PFE

Pfizer Inc. discovers, develops, manufactures, and commercializes biopharmaceutical products worldwide. Headquartered in New York City, the company operates through two primary business segments: Biopharmaceuticals and Established Medicines. Pfizer's portfolio includes treatments across multiple therapeutic areas including oncology, inflammation and immunology, rare diseases, vaccines, and internal medicine. The company employs approximately 83,000 people globally and generates annual revenues exceeding $58 billion. Key products include Comirnaty (COVID-19 vaccine developed with BioNTech), Paxlovid (oral COVID-19 treatment), Eliquis (anticoagulant), Ibrance (breast cancer treatment), and Prevnar family (pneumococcal vaccines). Pfizer ranks among the world's largest pharmaceutical companies by revenue and market capitalization. In 2023, the company completed its $43 billion acquisition of Seagen, a leading oncology-focused biotech, significantly expanding its cancer treatment portfolio and pipeline. The acquisition adds four marketed products and over 30 programs in clinical development. Pfizer maintains one of the industry's most robust research and development operations, investing heavily in innovative therapies and vaccines. The company markets products in more than 125 countries and operates manufacturing facilities across multiple continents, maintaining a strong global supply chain infrastructure that supports its diverse product portfolio and worldwide distribution capabilities.